Pine Pharmaceuticals (United States) has no DMF, CEP or site registration linked in our records. 50 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Pine Pharmaceuticals: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/pine-pharmaceuticals

Overview

Pine Pharmaceuticals is a pharmaceutical company headquartered in Tonawanda, United States.

FDA compliance signals

50 FDA enforcement records linked to this company.

  • warning_letter2026-08-07

    FDA Warning Letter (drug product)

  • 4832024-09-30

    Environmental Monitoring System

  • 4832024-09-30

    Written in-process control procedures

  • 4832024-09-30

    Absence of Written Procedures

  • 4832024-09-30

    Actual vs. theoretical yields not determined

  • 4832024-09-30

    Mfg / Processing Operations Area

  • 4832024-09-30

    Air Supply

  • 4832024-09-30

    Procedures for sterile drug products

  • 4832024-09-30

    Cleaning System

  • 4832024-09-30

    Investigations of discrepancies, failures

  • recall — Class II2023-10-25

    Lack of Assurance of Sterility

  • recall — Class II2023-10-25

    Lack of Assurance of Sterility

  • recall — Class II2023-10-25

    Lack of Assurance of Sterility

  • recall — Class II2023-10-25

    Lack of Assurance of Sterility

  • recall — Class II2023-10-25

    Lack of Assurance of Sterility

  • recall — Class II2023-10-25

    Lack of Assurance of Sterility

  • recall — Class II2023-10-25

    Lack of Assurance of Sterility

  • recall — Class II2023-10-25

    Lack of Assurance of Sterility

  • recall — Class II2023-10-25

    Lack of Assurance of Sterility

  • recall — Class II2023-10-25

    Lack of Assurance of Sterility

  • recall — Class II2023-10-25

    Lack of Assurance of Sterility

  • recall — Class II2023-10-25

    Lack of Assurance of Sterility

  • recall — Class II2023-10-25

    Lack of Assurance of Sterility

  • recall — Class II2023-10-25

    Lack of Assurance of Sterility

  • recall — Class II2023-10-25

    Lack of Assurance of Sterility

  • recall — Class II2023-10-25

    Lack of Assurance of Sterility

  • 4832023-09-19

    Procedures for sterile drug products

  • 4832023-09-19

    Investigations of discrepancies, failures

  • 4832023-09-19

    Outsourcing facility, compounded drug report follow up

  • 4832023-09-19

    Production areas, difficult to clean/particle generating

  • 4832023-09-19

    Inadequate smoke studies

  • 4832023-09-19

    Approve or reject components, products

  • 4832023-09-19

    Personnel, blocked or disrupted first air

  • recall — Class III2023-04-19

    Labeling: Incorrect or Missing Lot and/or Exp Date: Lot code on primary packaging is incorrect.

  • recall — Class II2023-01-11

    CGMP Deviations: Raw material recalled by repackager, due to discoloration.

  • recall — Class II2022-09-21

    Lack of Assurance of Sterility

  • 4832021-05-14

    Written calibration / inspection records not kept

  • 4832021-05-14

    Procedures for sterile drug products

  • 4832021-05-14

    Approve or reject procedures or specs

  • 4832021-05-14

    Scientifically sound laboratory controls

  • 4832021-05-14

    Investigations of discrepancies, failures

  • 4832018-04-26

    Procedures for sterile drug products

  • 4832018-04-26

    Strict control not exercised over labeling issued

  • 4832018-04-26

    Training , Education , Experience overall

  • recall — Class III2018-03-28

    Labeling: Label Mix-Up: Brilliant Blue G was labeled with an inaccurate auxiliary label which contained active/inactive ingredient information for incorrect product.

  • warning_letter2016-11-07

    FDA Warning Letter (drug product)

  • recall — Class II2016-01-27

    Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitreal use.

  • recall — Class II2016-01-27

    Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitreal use.

  • recall — Class II2016-01-27

    Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitreal use.

  • recall — Class II2016-01-27

    Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitreal use.

For suppliers

Is this Pine Pharmaceuticals?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.